Particle.news
Download on the App Store
8 ARTICLES
·
5h ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

The webcast will deliver the first Phase 3 readout for azetukalner in focal onset seizures.

Ian Mortimer, CEO of Xenon, poses for a photograph at the lab in Burnaby, B.C, on Friday, December 1, 2023. Tijana Martin/ The Globe and Mail
Image

Overview

  • The announcement is scheduled for Monday, March 9, 2026, at 8:00 a.m. ET with Conference ID 7885306 and dial‑in numbers (800) 715‑9871 toll‑free or (646) 307‑1963 for international callers.
  • A live webcast requires pre‑registration, and a replay will be posted on the Investors section of Xenon’s website after the event.
  • Xenon states the listed date and time are subject to change.
  • Azetukalner is a novel, potent KV7 potassium channel opener being evaluated for focal onset seizures.
  • The molecule is also in Phase 3 studies for major depressive disorder and bipolar depression, and Xenon is advancing KV7 and NaV1.7 pain programs in Phase 1.